换一批
换一批BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
作者：
主题词
动物(Animals);抗肿瘤药(Antineoplastic Agents);苯甲酰胺类(Benzamides);苯咪唑类(Benzimidazoles);癌(Carcinoma);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);二苯胺(Diphenylamine);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);人类(Humans);小鼠(Mice);小鼠, 裸(Mice, Nude);丝裂原激活蛋白激酶激酶类(Mitogen-Activated Protein Kinase Kinases);突变, 误义(Mutation, Missense);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);底物特异性(Substrate Specificity);甲状腺肿瘤(Thyroid Neoplasms);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.1210/jc.2007-2825
PMID
18381570
发布时间
2022-03-16
- 浏览26
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
